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The interferon-c (IFNc)–inducible IRG
proteins are a distinctive cytoplasmic
GTPase family encoded by about 20 genes
in the C57BL/6 mouse [1]. All four IRG
genes that have been knocked out (Irgm1,
Irgm3, Irgd, Irga6) have caused more or
less striking susceptibility phenotypes to
Toxoplasma gondii ([2,3] and O. Liesenfeld,
I. Parvanova, J. Zerrahn, S-J. Han, F.
Heinrich, et al., unpublished data). How-
ever, one single member of the IRG
family, Irgm1 (formerly called LRG-47),
stands out because it has additionally been
implicated in a remarkable range of
resistances in the mouse: resistance to
Trypanosoma cruzi [4], Leishmania major [5],
Listeria monocytogenes [2], Mycobacterium tu-
berculosis [6], Mycobacterium avium [7], Chla-
mydia trachomatis [8], and Salmonella typhi-
murium [9]. These are all intracellular but
otherwise very different organisms—some
are protozoa, some Gram-negative bacte-
ria, some Gram-positive, some living
inside a vacuole or phagosome, and some
free in the cytosol. Thus, Irgm1 appears to
have exceptional properties of disease
resistance not shared by other members
of the IRG family.
Specific cell-autonomous resistance
mechanisms have been attributed to
Irgm1 in the context of mycobacterial
resistance. Irgm1 has been considered to
act by associating with the mycobacterial
phagosomal membrane and accelerating
lysosomal fusion [6] (Figure 1). There have
also been suggestions that under certain
conditions the protein can enhance the
formation of autophagosomes that in turn
control the pathogen [10–12]. These
activities, related but distinct, could both
be attractive candidates for a relatively
direct mode of action of Irgm1 as a
resistance protein.
These mechanisms for Irgm1 function
are widely accepted, perhaps partly be-
cause of the importance of the diseases
that they are supposed to control, but also
because, right or wrong, they are imme-
diately appreciable, plausible, proximal,
cell-autonomous effects on the pathogen.
However, optimism that there may be
such direct explanations for the loss of
mycobacterial resistance as a result of the
loss of Irgm1 has apparently obscured an
important literature on Irgm1 deficiency
and activity that points in an entirely
different direction.
Irgm1-deficient mice become strikingly
leukopenic when infected with mycobac-
teria. Alan Sher and colleagues reported
some years ago that the blood picture of
young Irgm1-deficient adults is pretty
normal, but collapses during infection
[7]. They subsequently observed the same
phenomenon for Trypanosoma infection [4].
A complete catalog has not yet been made,
but we may infer that leukopenia is the
rule when Irgm1-deficient mice are infect-
ed with any immunostimulatory pathogen.
Indeed, induced lymphopenia seems also
to arise following non-pathogenic immune
stimuli since induction of experimental
allergic encephalitis in Irgm1-deficient
mice with myelin basic protein peptides,
a well-established model for multiple
sclerosis, resulted in similar leukocytic
defects, in this case with a beneficial
outcome for the disease [13]. Thus we
ask, does susceptibility to mycobacteria (or
T. cruzi or Salmonella) really have something
to do with the proposed cell-autonomous
mechanisms, autophagocytosis or reduced
vacuole acidification, or is it due to the
profound and generalized immunodefi-
ciency that these organisms induce in
Irgm1-deficient hosts?
Gregory Taylor and colleagues showed
recently that mice that are not only Irgm1-
but also Irgm3-deficient (that is, they have
a doubly deficient IRG system) are no
longer susceptible to Salmonella [14] (see
Table 1). Furthermore, the authors cite a
personal communication from John Mac-
Micking that the mycobacterial suscepti-
bility phenotype of Irgm1-single-deficient
mice is also reversed in the same double
knock-out. Thus the absence of Irgm1
cannot be the direct cause of the suscepti-
bility in either of these cases. There must
be a more complex explanation.
Why do Irgm1-deficient animals rapidly
develop a lymphomyeloid deficiency after
infection or autoimmune stimulation?
There seems to be reduced proliferative
potential in the lymphomyeloid system
that becomes acute after immune activa-
tion. It was shown recently that this affects
the hematopoietic stem cell (HSC) as well
as more peripheral lymphoid compart-
ments [15]. The functional impairment
depends absolutely on the presence of
IFNc and the integrity of its signal
transduction pathway. If these are im-
paired or impeded, the Irgm1-dependent
hematopoietic and lymphopoietic failures
are reversed, as is susceptibility to infection
by mycobacteria ([16,17]; Margaret
Goodell, personal communication). Thus,
absence of Irgm1 is not in itself responsible
for the hemopoietic and immune failures.
Rather, it is the rest of the IFN response
that is causing the problem in the absence
of Irgm1. Stressing this point, Irgm1-
deficient mice infected with a pathogen
that stimulates only a Th2 response
(Schistosoma mansoni), and therefore essen-
tially no IFNc production, show normal
resistance and no lymphoid abnormalities
[16]. Which of the thousand or so IFNc-
regulated transcripts is responsible for this
mysterious effect? The double knock-out
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interesting answer, that the problem with
Irgm1 deficiency is connected with the
presence of the rest of the IRG family of
proteins. What can that problem be?
We showed that the IRG proteins fall
into two groups, the GKS and the GMS
sub-families, based on the sequence of
their nucleotide binding domains [18].
More recently, we showed that the three
GMS proteins, Irgm1 (LRG-47), Irgm2
(GTPI), and Irgm3 (IGTP), are essential
regulators of the GTPase cycle of the GKS
proteins, binding to these in the GDP-
bound state and acting as attenuators,
preventing premature activation of GKS
proteins by the binding of GTP [19]. If
even only one of the three GMS regulator
proteins is absent, the GKS effector
proteins form GTP-bound aggregates in
the cell [19,20]. Under these conditions,
the GKS proteins can no longer exercise
their only confirmed function of relocating
to the T. gondii vacuole and initiating
vacuolar disruption [21] (see Figure 1). For
still unclear reasons, all three GMS
proteins must be present for normal
behavior of the GKS proteins.
It was shown some time ago that
unregulated GKS proteins can interfere
with cell proliferation. Douglas Carlow
and colleagues attempted to generate
fibroblast cell lines constitutively express-
ing the GKS effector IRG protein Irgb6 in
the absence of IFNc, and therefore in the
absence of the three GMS proteins [22].
These cell lines regularly lost expression of
the protein, and they showed only limited
stability even when expressing very low
levels of the protein. Constitutive expres-
sion of Irga6 in cells in the absence of
IFNc led to the formation of protein
aggregates associated with marked patho-
logical expansion of the endoplasmic
reticulum lumen, though apparently with-
out interfering with cell proliferation of
mouse 3T3 fibroblasts [19]. It is worth
mentioning that expression of individual
GMS proteins has no detectable cytopath-
ic or cytostatic effect on cells growing in
culture ([19] and J. Hunn, S. Ko ¨nen-
Waisman, J. Howard, unpublished data).
We can therefore propose the following
preliminary scenario for the Irgm1-defi-
cient mouse. In the absence of induced
IFNc production, the mouse appears
relatively normal. However, for unclear
reasons, there is constitutive expression of
many IRG genes in HSCs [23–25]. In the
absence of Irgm1, this expression would be
expected to result in unregulated cytoplas-
mic aggregates of GKS proteins. These
are presumably cytostatic or cytopathic in
the HSC population, resulting in contin-
uous turnover and concomitant near
exhaustion of the stem cell pool, leaving
little residual potential to respond to
hematopoietic stress [15]. In the periph-
ery, infection rapidly induces IFNc, which
in turn induces the IRG protein response
in lymphoid and other cells. As in HSC,
Irgm1 deficiency results in the formation
of intracellular aggregates of unregulated
GKS proteins [14,19,20]. These aggre-
gates are presumably cytostatic or cyto-
pathic for cells of the lymphomyeloid
system, perhaps especially for replicating
cells through inhibition of the ubiquitin-
proteasome system [26], resulting in the
observed infection-induced leukopenia
and a generalized immunodeficiency. It
seems that IRG aggregate formation must
also be toxic for interphase lymphocytes to
explain the generalized lymphopenia. We
would argue that the deposition of aggre-
gates in IFNc-induced cells is responsible
for the autophagic anomalies observed in
Irgm1-deficient T lymphocytes [16].
Consistent with this scenario, Taylor
and colleagues showed aggregates of GKS
proteins (Irgb6 and Irga6) in bone mar-
row–derived macrophages from Irgm1
knock-out mice after in vitro stimulation
with IFNc [14]. However, they also
observed aggregates in IFNc-induced cells
from Irgm3 knock-outs and Irgm1/Irgm3
double knock-outs, neither of which show
a significant lymphopenia nor susceptibil-
ity phenotype to Salmonella or mycobacte-
ria infection [6,9]. At first glance, this
latter observation seems to argue against
the idea that protein aggregates are
Figure 1. Irgm1 in cell-autonomous immunity. (Left) In the wild-type, IFNc-treated cell, IRG
proteins are induced and both T. gondii (A) and mycobacteria (B) are killed. Many IRG proteins
accumulate around the T. gondii vacuole (indicated in red at (A)), while only the normally Golgi-
associated Irgm1 (green) is thought to accumulate around the mycobacterial phagosome [6,36].
There is little doubt that destruction of T. gondii is initiated by an IRG protein–mediated direct
attack on the parasitophorous vacuole membrane [21]. It has been argued that Irgm1 on the
mycobacterial phagosome membrane is directly responsible for fast acidification of the
phagosome by lysosomal fusion ([6], indicated in grey at (B)) and perhaps also for initiation of
autophagy [10]. (Right) Loss of Irgm1 results in loss of control of both T. gondii and
mycobacteria. However, Irgm1 is one of three essential regulatory proteins belonging to the GMS
subfamily of IRG proteins (Irgm1, Irgm2, Irgm3), that prevent premature activation of the GKS
subfamily IRG proteins (Irga6, Irgb6, Irgd, etc.; red) in IFNc-induced cells [19]. Loss of Irgm1 causes
the normally markedly cytosolic GKS proteins (shaded red on the left) to form large, GTP-bound,
non-functional aggregates (red dots) in IFNc-induced cells [14] with striking cytopathic effects,
especially on cells of the lymphomyeloid system [7,15]. We argue that this, rather than loss of
Irgm1 from the mycobacterial phagosome, is the main reason for the dramatic immune
impairment of Irgm1-deficient mice, including loss of mycobacterial resistance.
doi:10.1371/journal.ppat.1001008.g001
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Irgm1 loss [14]. However, aggregates
forming as a result of Irgm1 deficiency
may well be qualitatively distinct from,
and more cytotoxic than, those resulting
from Irgm3 deficiency. We have shown
that all three GMS regulators are required
for complete GKS control and have
hypothesized that each is required for
GKS regulation on a different group of
endomembranes [19]. Thus, Irgm1 defi-
ciency may lead preferentially to GKS
aggregation on Golgi and endolysosomal
membranes, where Irgm1 is normally
localized [27,28], while aggregates due to
Irgm3 deficiency form preferentially on
endoplasmic reticulum membranes, where
Irgm3 is normally localized [29]. There is
already evidence that Irga6 and Irgb6 may
be preferentially regulated to a different
extent by individual GMS proteins [19].
Such distinctions may well result in
different cytopathic phenotypes for differ-
ent GMS deficiencies depending on the
level and subcellular localization of dys-
regulation. Taylor and colleagues also
noticed that there was a reduced amount
of GKS IRG proteins in IFNc-induced
Irgm3-deficient macrophages compared
with the wild-type or Irgm1-deficient cells
[14]. In the Irgm1/Irgm3 double knock-
out cells the amount of GKS protein was
very greatly reduced. This is presumably
due to a substantially reduced half-life of
aggregated GKS protein. Thus, there may
be a quantitative as well as a qualitative
reason for the heightened cytopathic
effects of Irgm1 deficiency compared with
Irgm3 deficiency. An alternative view, that
Irgm3 is cytopathic in the absence of
Irgm1, we consider less convincing. There
is no a priori basis for the supposition, and
cells expressing Irgm3 alone, by transfec-
tion, show no cytopathic or proliferative
anomalies, and the protein does not form
intracellular aggregates ([19,29] and J.
Hunn, S. Ko ¨nen-Waisman, J. Howard,
unpublished data).
A plausible interpretation of the Irgm1
phenomenon now runs like this. Infection,
for example by mycobacteria, induces a
high level of IFNc, which in turn induces
high levels of IRG proteins. In the absence
of Irgm1, the GTPase cycle of the
remaining IRG proteins cannot be prop-
erly controlled. This results in the forma-
tion of large IRG protein aggregates that
in certain cell types of the hematopoietic
and lymphoid systems are cytopathic or
cytostatic, causing a generalized lympho-
penia. Losing Irgm3 and Irgm1 together
causes rapid clearance of the aggregates
and relieves the cytopathic phenotype.
Thus, in the Irgm1/Irgm3 double knock-
out the immune picture essentially returns
to normal. In a recent note, Feng and
colleagues have also proposed that at least
part of the Irgm1 deficiency phenotype is
due to the loss of a regulatory function
[17]. However, our interpretation differs
significantly from theirs. They propose a
specific role for Irgm1 in the maintenance
of T cell survival following IFNc induc-
tion, while we view the function of Irgm1
to be confined to its regulatory activity in
the GTPase cycle of the GKS IRG
proteins and the prevention of aggrega-
tion. Their position, attributing a positive
regulatory effect by Irgm1 inhibiting an
autophagy-mediated cell death, seems to
offer no explanation for the loss of the
Irgm1 deficiency phenotype in the Irgm1/
m3 double-deficient mouse.
Resistance to Toxoplasma is completely
lost in the Irgm1 knock-out [2], and this
could of course as easily be due to the
generalized immunodeficiency as to the
loss of a key IRG protein function.
However, resistance to Toxoplasma does
not return in the Irgm1/Irgm3 double
knock-out [14]. Furthermore, loss of Irgd
or Irga6, both GKS proteins, also leads to
a Toxoplasma susceptibility phenotype with-
out any lymphopenia or generalized
immunodeficiency ([2,21] and O. Liesen-
feld, I. Parvanova, J. Zerrahn, S-J. Han, F.
Heinrich, et al., unpublished data). The
conclusion is that the IRG proteins really
do mediate resistance against Toxoplasma in
mice. It is a good bet that the ability of
multiple IRG proteins to relocalize to the
T. gondii parasitophorous vacuole mem-
brane, causing its disruption and killing
the parasite [21,30], indicates the essential
mechanism by which IRG proteins oper-
ate against this pathogen.
We conclude that the adaptive role of
Irgm1 in mice is connected to its activity in
the regulation of the GKS members of the
IRG protein family. T. gondii is probably
an important pathogen for mice because
of the recent predominance of the domes-
tic cat as definitive host, and it may
therefore be that resistance to this parasite
is driving the function of the IRG system
in the mouse. Recent results from Jo ¨rn
Table 1. Summary of cellular and systemic consequences of IRGM knock-outs.
Genotype
Wt Normal expression and regulation of induced effector IRG proteins
No cytopathic consequences for cellular function
Heightened cell-autonomous immunity via IRG proteins
Resistance against a wide range of intracellular pathogens
a
Irgm1
2/2 Incomplete regulation of induced effector IRG proteins
Cytosolic aggregates of IRG proteins with cytopathic consequences:
- Stem cell exhaustion
- Massive leukopenia
- Systemic immune deficiency
- Macrophage dysfunction: reduced motility, impaired adhesiveness,
reduced phagosome acidification, multiple cell-autonomous immune
deficiencies
Susceptibility to multiple pathogens including mycobacteria,
Salmonella, Trypanosoma,a n dLeishmania in addition to C. trachomatis and
T. gondii
Irgm1/m3
2/2 Incomplete regulation of induced effector IRG proteins
Strongly reduced expression of effector IRG proteins
Cytosolic aggregates of IRG proteins with enhanced clearance
and no cytopathic consequences:
- No stem cell exhaustion
- No leukopenia
- No systemic immune deficiency
- No cell-autonomous dysfunction except loss of IRG-dependent immunity
Susceptibility only to T. gondii and C. trachomatis
a
This table summarizes the arguments presented, documented, and referenced in the accompanying article.
Each panel can be read from top to bottom as a causal chain. Thus, Irgm1 deficiency results in incomplete
regulation of induced effector GKS IRG proteins, which results in build up of cytosolic aggregates, and these
in turn have cytopathic consequences. For Irgm1 deficiency, the causal chain is long and ends up with major
systemic and cell-autonomous immunodeficiency. In wild-type cells, the causal chain is adaptive and leads to
increased cell-autonomous immune competence, while in the Irgm1/Irgm3 double-deficient cells the causal
chain heading towards cytopathy is truncated by the rapid clearance of the IRG protein aggregates. The
consequences of Irgm1 deficiency are cellular as well as systemic and result in whole-animal immune failure.
aThe range of pathogens genuinely controlled by the IRG system of mice is unclear. At present, T. gondii and
C. trachomatis stand out, but it is not known what these two pathogens have in common that renders them
susceptible to IRG-mediated immunity, nor what the other organisms lack or possess that renders them
resistant.
doi:10.1371/journal.ppat.1001008.t001
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system may also be directly active against
C. trachomatis [8,31]. However, we consider
it highly unlikely that Irgm1 has any
adaptive function at all in resistance
against most of the other pathogens
attributed to it. Certainly mycobacteria
and Salmonella can now be explicitly
excluded [6,9], and there is every reason
to suppose that most if not all the others
except T. gondii and C. trachomatis will go
the same way.
It is important to look back on the
experiments that attributed specific cell-
autonomous activities to Irgm1 to account
for its role in resistance to mycobacteria. If
resistance to mycobacteria or Salmonella
really has nothing to do with IRG
proteins, why does Irgm1 relocalize to
the mycobacterial phagosome, and why
would acidification of the phagosome be
reduced in Irgm1-deficient cells [6] (see
Figure 1)? Most of the relevant experi-
ments were conducted on macrophages
derived from the Irgm1-deficient strain, so
it is the properties of macrophages that
should be considered. As to the first point,
it was shown some years ago that Irgm1
relocalizes to latex bead phagosomes in
macrophages [27], so this step has nothing
necessarily to do with mycobacterial
infection. To the second point, Taylor
and colleagues have described striking cell-
autonomous abnormalities in the motility
and adhesiveness of macrophages derived
from Irgm1-deficient mice [9,14,32].
These defects are completely reversed in
the Irgm1/Irgm3 double knock-out [14].
In view of the hematopoietic abnormalities
in the Irgm1-deficient mice, macrophage
development and differentiation are prob-
ably also disturbed. Aggregate formation
in Irgm1-deficient macrophages [14] may
also have direct cytopathic consequences
for many aspects of macrophage activity,
including lysosomal function, perhaps as a
result of autophagy, constitutively stimu-
lated by the presence of IRG protein
aggregates [33]. Therefore, a direct com-
parison between the cell-autonomous
properties, such as phagocytic vacuole
acidification and induction of autophagy,
of Irgm1-deficient and wild-type macro-
phages is probably not valid. A direct
analysis of phagosome and autophago-
some function in the single and double
GMS knock-outs would clarify whether
some direct cell-autonomous function can
be attributed to Irgm1.
It is also interesting to revisit the
specificity control introduced by Taylor
and colleagues to indicate that the im-
mune deficiency due to Irgm1 was not
universal, namely that resistance to mouse
cytomegalovirus (MCMV) was normal
[2,3]. Resistance to MCMV does not
depend on T cells but is largely mediated
by natural killer cells, which require
cytokine-mediated activation to develop
full functional activity [34,35]. This cell
type may be less vulnerable to the
cytopathic consequences of Irgm1 defi-
ciency than T cells and HSCs.
It is important to emphasize that while
the present view can account for much of
the complexity of the observations on
Irgm1 deficiency, it remains possible that
Irgm1 may have additional ‘‘autonomous’’
activities of its own, perhaps in the control
of autophagy. It now seems unlikely that
this will be true for immunity against
mycobacteria or Salmonella since this ap-
pears to be normal in the absence of Irgm1
so long as Irgm3 is missing too, but these,
of course, do not exhaust the universe of
intracellular pathogens. There is much
experimental work left to do to assess the
validity and completeness of this revision
of view about how the IRG proteins fulfill
their function. It is a complex argument,
but it hangs together reasonably well
and offers a broad and satisfying explana-
tion for most, if not all, of the properties
of the Irgm1-deficient mouse. Above all,
however, the IRG system must be under-
stood as a highly regulated, highly coordi-
nated system of proteins where the prop-
erties of single-gene knock-outs may be
misleading.
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